LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP5 | 1 | C19 | 72 | hr | 868 | 309 | 3486 | 0.0886 | -0.2135 |
MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP5 | 2 | C19 | 72 | hr | 868 | 372 | 3486 | 0.1067 | -0.1895 |
MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP5 | 3 | C19 | 72 | hr | 868 | 312 | 3486 | 0.0895 | -0.2124 |
MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP6 | 1 | C19 | 72 | hr | 868 | 289 | 3486 | 0.0829 | -0.2212 |
MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP6 | 2 | C19 | 72 | hr | 868 | 305 | 3486 | 0.0875 | -0.2151 |
MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP6 | 3 | C19 | 72 | hr | 868 | 276 | 3486 | 0.0792 | -0.2262 |
MDA-MB-231 | MK2206 | 10.0 | uM | LJP6 | 1 | F01 | 72 | hr | 868 | 1122 | 3486 | 0.3218 | 0.0970 |
MDA-MB-231 | MK2206 | 10.0 | uM | LJP6 | 2 | F01 | 72 | hr | 868 | 1014 | 3486 | 0.2908 | 0.0557 |
MDA-MB-231 | MK2206 | 10.0 | uM | LJP6 | 3 | F01 | 72 | hr | 868 | 1282 | 3486 | 0.3677 | 0.1581 |
MDA-MB-231 | Neratinib | 10.0 | uM | LJP5 | 1 | A13 | 72 | hr | 868 | 722 | 3486 | 0.2071 | -0.0558 |
MDA-MB-231 | Neratinib | 10.0 | uM | LJP5 | 2 | A13 | 72 | hr | 868 | 664 | 3486 | 0.1905 | -0.0780 |
MDA-MB-231 | Neratinib | 10.0 | uM | LJP5 | 3 | A13 | 72 | hr | 868 | 759 | 3486 | 0.2177 | -0.0417 |
MDA-MB-231 | Nilotinib | 10.0 | uM | LJP5 | 1 | N13 | 72 | hr | 868 | 1123 | 3486 | 0.3221 | 0.0973 |
MDA-MB-231 | Nilotinib | 10.0 | uM | LJP5 | 2 | N13 | 72 | hr | 868 | 1339 | 3486 | 0.3841 | 0.1798 |
MDA-MB-231 | Nilotinib | 10.0 | uM | LJP5 | 3 | N13 | 72 | hr | 868 | 1245 | 3486 | 0.3571 | 0.1439 |
MDA-MB-231 | Nintedanib | 10.0 | uM | LJP6 | 1 | H01 | 72 | hr | 868 | 582 | 3486 | 0.1669 | -0.1093 |
MDA-MB-231 | Nintedanib | 10.0 | uM | LJP6 | 2 | H01 | 72 | hr | 868 | 634 | 3486 | 0.1819 | -0.0894 |
MDA-MB-231 | Nintedanib | 10.0 | uM | LJP6 | 3 | H01 | 72 | hr | 868 | 708 | 3486 | 0.2031 | -0.0612 |
MDA-MB-231 | NU7441 | 10.0 | uM | LJP5 | 1 | C07 | 72 | hr | 868 | 1152 | 3486 | 0.3304 | 0.1084 |
MDA-MB-231 | NU7441 | 10.0 | uM | LJP5 | 2 | C07 | 72 | hr | 868 | 1184 | 3486 | 0.3396 | 0.1206 |
MDA-MB-231 | NU7441 | 10.0 | uM | LJP5 | 3 | C07 | 72 | hr | 868 | 1143 | 3486 | 0.3279 | 0.1050 |
MDA-MB-231 | Dactolisib | 10.0 | uM | LJP5 | 1 | M13 | 72 | hr | 868 | 1548 | 3486 | 0.4440 | 0.2597 |
MDA-MB-231 | Dactolisib | 10.0 | uM | LJP5 | 2 | M13 | 72 | hr | 868 | 1561 | 3486 | 0.4477 | 0.2646 |
MDA-MB-231 | Dactolisib | 10.0 | uM | LJP5 | 3 | M13 | 72 | hr | 868 | 1556 | 3486 | 0.4463 | 0.2627 |
MDA-MB-231 | NVP-TAE684 | 10.0 | uM | LJP6 | 1 | K13 | 72 | hr | 868 | 678 | 3486 | 0.1945 | -0.0726 |